Cedric Francois, Apellis CEO
FDA delays decision for Apellis' eye disease drug after biotech submits updated data
Apellis had secured a priority review for its geographic atrophy program, but it turns out the FDA wants to wait a little bit longer before …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
